Yesterday, miners underperformed after weak Chinese inflation cause metal prices to drop. The FTSE ended Monday’s session 0.3% higher. Rio Tinto gained 2.2% after J.P. Morgan upgraded its rating to "overweight" from "neutral".

New data published this morning strengthened the case for a more dovish policy from the BoE. It shows regular wages grew by 7.3% in the three months to October in the UK, slightly below the forecasted 7.4%.

In other news, Britain's Financial Conduct Authority (FCA) has written to UK investment platforms to voice its concerns about the amount of interest and fees charged by some of them, warning it could act to ensure fair value.

Among stocks, MaxCyte, which specializes in cell-engineering technologies, updated its revenue guidance, expecting core revenue of $28 million to $30 million for 2023 and SPL program-related revenue of at least $10 million, up from the previous $6 million estimate. Its stock price saw a 4.4% decrease.

AstraZeneca is set to acquire Icosavax Inc for up to $1.1 billion, enhancing its vaccine portfolio with a treatment for respiratory viruses. The deal includes an initial tender offer for Icosavax shares at $15.00 each, with additional contingent value rights.

Chemring Group PLC reported an 18% revenue increase to £472.6 million and a 24% jump in underlying pretax profit. However, statutory pretax profit fell by 7.9%. The company raised its dividend by 21% to 6.9 pence per share, citing modernization needs in NATO's defense capabilities.

Meanwhile, Unilever faces a UK probe into its environmental claims about household products, with the Competition and Markets Authority investigating whether the company overstated the "green" aspect of certain items.

Investors’ focus is turning to the November U.S. consumer prices data, ahead of the Federal Reserve’s monetary policy decision.

Things to read today: